Drive Wealth Management LLC Sells 1,058 Shares of AstraZeneca PLC (NASDAQ:AZN)

Drive Wealth Management LLC reduced its position in AstraZeneca PLC (NASDAQ:AZN) by 24.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,193 shares of the company’s stock after selling 1,058 shares during the quarter. Drive Wealth Management LLC’s holdings in AstraZeneca were worth $209,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Bank of Montreal Can lifted its position in AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares during the last quarter. Franklin Resources Inc. lifted its position in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after purchasing an additional 1,522,715 shares during the last quarter. Erste Asset Management GmbH bought a new stake in AstraZeneca during the third quarter valued at approximately $72,437,000. Fisher Asset Management LLC lifted its position in AstraZeneca by 5.3% during the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after purchasing an additional 524,175 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in AstraZeneca by 63.5% during the third quarter. Assenagon Asset Management S.A. now owns 871,893 shares of the company’s stock valued at $67,929,000 after purchasing an additional 338,566 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AZN has been the subject of several research analyst reports. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 1.5 %

AZN stock opened at $70.08 on Tuesday. The company has a market capitalization of $217.32 billion, a PE ratio of 33.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company’s 50 day moving average price is $66.44 and its two-hundred day moving average price is $74.14. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the firm posted $0.87 earnings per share. The business’s revenue was up 18.0% compared to the same quarter last year. As a group, analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.